Sage Journals: Discover world-class research

Abstract

Background

The incremental prognostic value of assessing the metabolic syndrome has been disputed. Little is known regarding its prognostic value in patients after an acute coronary syndrome.

Design and methods

The presence of metabolic syndrome (2005 International Diabetes Federation) was assessed at baseline in SOLID-TIMI 52, a trial of patients within 30 days of acute coronary syndrome (median follow-up 2.5 years). The primary endpoint was major coronary events (coronary heart disease death, myocardial infarction or urgent coronary revascularization).

Results

At baseline, 61.6% (n = 7537) of patients met the definition of metabolic syndrome, 34.7% (n = 4247) had diabetes and 29.3% had both (n = 3584). The presence of metabolic syndrome was associated with increased risk of major coronary events (adjusted hazard ratio (adjHR) 1.29, p < 0.0001) and recurrent myocardial infarction (adjHR 1.30, p < 0.0001). Of the individual components of the definition, only diabetes (adjHR 1.48, p < 0.0001) or impaired fasting glucose (adjHR 1.21, p = 0.002) and hypertension (adjHR 1.46, p < 0.0001) were associated with the risk of major coronary events. In patients without diabetes, metabolic syndrome was numerically but not significantly associated with the risk of major coronary events (adjHR 1.13, p = 0.06). Conversely, diabetes was a strong independent predictor of major coronary events in the absence of metabolic syndrome (adjHR 1.57, p < 0.0001). The presence of both diabetes and metabolic syndrome identified patients at highest risk of adverse outcomes but the incremental value of metabolic syndrome was not significant relative to diabetes alone (adjHR 1.07, p = 0.54).

Conclusions

After acute coronary syndrome, diabetes is a strong and independent predictor of adverse outcomes. Assessment of the metabolic syndrome provides only marginal incremental value once the presence or absence of diabetes is established.

Keywords

Metabolic syndrome diabetes acute coronary syndrome

Get full access to this article

View all access options for this article.

References

Wilson

Kannel

Silbershatz

et al.

Clustering of metabolic factors and coronary heart disease. Arch Intern Med 1999; 159: 1104–1109.

Aguilar

Bhuket

Torres

et al.

Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA 2015; 313: 1973–1974.

Mottillo

Filion

Genest

et al.

The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113–1132.

Kahn

Buse

Ferrannini

et al.

The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289–2304.

Norhammar

Mellbin

Cosentino

. Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor. Eur J Prev Cardiol 2017; 24(3 Suppl.): 52–60.

Maddaloni

Pozzilli

. SMART diabetes: The way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in diabetes). Endocrine 2014; 46: 3–5.

O’Donoghue

Braunwald

White

et al.

Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial. JAMA 2014; 312: 1006–1115.

O’Donoghue

Braunwald

White

et al.

Study design and rationale for the Stabilization of pLaques using Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J 2011; 162: 613–619.

The IDF consensus worldwide definition of the metabolic syndrome 2005, https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome (2006, accessed 26 May 2017).

10.

Grundy

Cleeman

Daniels

et al.

Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–2752.

11.

Netzer

Stoohs

Netzer

et al.

Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 1999; 131: 485–1491.

12.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.

13.

Reaven

. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.

14.

DeFronzo

Ferrannini

. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–194.

15.

Baron

. Hemodynamic actions of insulin. Am J Physiol 1994; 267: E187–E202.

16.

Haffner

Katz

Dunn

. Increased upper body and overall adiposity is associated with decreased sex hormone binding globulin in postmenopausal women. Int J Obes 1991; 15: 471–478.

17.

Galassi

Reynolds

. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med 2006; 119: 812–819.

18.

Gami

Witt

Howard

et al.

Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403–414.

19.

Lee

Lim

Shin

et al.

The impact of metabolic syndrome on clinical outcomes after everolimus-eluting stent implantation. Am J Cardiol 2015; 116: 717–724.

20.

Won

Kim

Chang

et al.

Metabolic syndrome does not impact long-term survival in patients with acute myocardial infarction after successful percutaneous coronary intervention with drug-eluting stents. Catheter Cardiovasc Interv 2014; 83: 713–720.

21.

Mehta

Westerhout

Zheng

et al.

Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non-ST-segment elevation acute coronary syndromes. Am Heart J 2014; 168: 182–188.

22.

Dohi

Miyauchi

Kasai

et al.

Impact of metabolic syndrome on 10-year clinical outcomes among patients with acute coronary syndrome. Circ J 2009; 73: 1454–1458.

23.

Boulon

Lafitte

Richeboeuf

et al.

Prevalence of metabolic syndrome after acute coronary syndrome and its prognostic significance. Am J Cardiol 2006; 98: 1429–1434.

24.

Isomaa

Almgren

Tuomi

et al.

Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–689.

25.

Lakka

Laaksonen

Lakka

et al.

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716.

26.

Ford

. The metabolic syndrome and mortality from cardiovascular disease and all-causes: Findings from the national health and nutrition examination survey II mortality study. Atherosclerosis 2004; 173: 309–314.

27.

Malik

Wong

Franklin

et al.

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245–1250.

28.

Butler

Rodondi

Zhu

et al.

Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol 2006; 47: 1595–1602.

29.

Monami

Marchionni

Masotti

et al.

IDF and ATP-III definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients. Diabetes Obes Metab 2007; 9: 350–353.

30.

Marroquin

Kip

Kelley

et al.

Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: A report from the women’s ischemia syndrome evaluation. Circulation 2004; 109: 714–721.

31.

Levantesi

Macchia

Marfisi

et al.

Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005; 46: 277–283.

32.

Feinberg

Schwartz

Tanne

et al.

Impact of the metabolic syndrome on the clinical outcomes of non-clinically diagnosed diabetic patients with acute coronary syndrome. Am J Cardiol 2007; 99: 667–672.

33.

Stern

Williams

Hunt

. Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease. Atheroscler Suppl 2005; 6: 3–6.

34.

Driver

Martin

Gluckman

et al.

Fasting or nonfasting lipid measurements: It depends on the question. J Am Coll Cardiol 2016; 67: 1227–1234.

35.

Bruthans

Mayer

Jr De Bacquer

et al.

Educational level and risk profile and risk control in patients with coronary heart disease. Eur J Prev Cardiol 2016; 23: 881–890.

36.

Kotseva

Wood

De Bacquer

et al.

EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23: 636–648.

37.

Schiele

Ecarnot

Chopard

. Coronary artery disease: Risk stratification and patient selection for more aggressive secondary prevention. Eur J Prev Cardiol 2017; 24(3 Suppl.): 88–100.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.33 MB

Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome

Abstract

Background

Design and methods

Results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material